Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Conclusion: Among real-world Chinese patients with ACS treated by PCI, ticagrelor only showed superior efficacy in patients with low bleeding risk but lost its advantage in patients with moderate-to-high bleeding potential.
PMID: 30127210 [PubMed - in process]
Source: Chinese Medical Journal - Category: General Medicine Authors: Wang HY, Li Y, Xu XM, Li J, Han YL Tags: Chin Med J (Engl) Source Type: research
More News: Angioplasty | Bleeding | China Health | Clopidogrel | Coronary Angioplasty | General Medicine | Heart Attack | Percutaneous Coronary Intervention | Plavix | Stroke | Study